Health Ministry Engages VIYA Health and Incepta to Expand Access to WHO-Pre-qualified Solution
Translated from English, summarized and contextualized by DistantNews.
TLDR
- VIYA Health Nigeria and Incepta Pharmaceuticals are partnering with the Nigerian Federal Ministry of Health to expand access to family planning solutions.
- The collaboration focuses on a WHO-prequalified generic version of DMPA-SC, a contraceptive injection, developed by Incepta and represented by VIYA Health in Nigeria.
- This initiative aims to help Nigeria achieve its target of a 27% Modern Contraceptive Prevalence Rate by 2030 by improving affordability and accessibility of discreet, convenient contraceptive options.
Nigeria is taking a significant step forward in reproductive health with a strategic engagement between the Federal Ministry of Health and Social Welfare and VIYA Health Nigeria, in partnership with Incepta Pharmaceuticals Ltd. This collaboration is set to dramatically expand access to high-quality family planning solutions, particularly focusing on the WHO-prequalified generic subcutaneous depot medroxyprogesterone acetate (DMPA-SC), branded as MedogenSubQ by Incepta and distributed by VIYA Health under the brand Meuri-SubQ.
VIYAโs mission to help women own their health and unlock economic, social, and personal power.
The significance of this partnership lies in its potential to address a critical need within Nigeria. The introduction of an affordable, innovative contraceptive option, supported by global organizations like the Children's Investment Fund Foundation and the Gates Foundation, is a major boost. VIYA Health's commitment to leveraging technology and data to empower women aligns perfectly with the Ministry's ambitious target of achieving a 27% Modern Contraceptive Prevalence Rate (mCPR) by 2030. This is not just about providing contraceptives; it's about enabling women to own their health and, by extension, unlock their economic, social, and personal potential.
the introduction of a WHO-prequalified generic DMPA-SC breaks the long-standing single-source supply bottleneck, improves affordability, and enables millions more women to access a discreet, convenient contraceptive option they can use independently.
From our perspective in Nigeria, this initiative represents a crucial advancement in healthcare accessibility. The dual-brand strategy ensures that the WHO-prequalified DMPA-SC reaches both the public and private sectors, strengthening the family planning market and building confidence among stakeholders. Billy Shoaga of VIYA Health rightly points out that this breaks the single-source supply bottleneck, making a discreet and convenient contraceptive option available to millions more women. This focus on self-care and strengthening health systems is vital for our national development goals. The proactive approach by the Ministry, engaging private sector partners, demonstrates a clear commitment to innovative solutions for pressing health challenges.
These efforts aim to strengthen health systems, advance self-care, and close access gaps to meet the rising demand for DMPA-SC in Nigeria.
Originally published by Premium Times in English. Translated, summarized, and contextualized by our editorial team with added local perspective. Read our editorial standards.